Janet Sasso

Information Scientist, CAS

Bio

Janet M. Sasso earned her B.S. in Biology from The Ohio State University (OSU). She also holds her Master of Public Health from OSU where she focused her research on public health equity and education. She joined CAS in 2006 as an Information Scientist in the life sciences department curating pharmacology, pharmaceutical, environmental science, and toxicological research information. She is passionate about scientific communication to accelerate scientific analysis and inspire advancement worldwide.

Emerging Science

Latest developments in the global mpox outbreak

With recent headlines on monkeypox, learn more about the research landscape, scientific profiles, and currently available therapies. A deeper understanding of the published science enables clarity and insight on this emerging news story.
|Article
Drug Discovery

Doenças raras e doenças órfãs: a terapia combinada pode tratá-las?

Como as terapias combinadas, incluindo reaproveitamento de medicamentos, terapia celular e terapia genética, estão levando a um melhor tratamento de doenças raras.
|Article
Emerging Science

Decoding neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's

Uncover the latest advancements in understanding and treating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s.
|Insights Report
Emerging Science

Webinar: Scientific breakthroughs and emerging trends to watch in 2024

Experts from Lawrence Livermore National Lab, Oak Ridge National Lab, The Ohio State University, and CAS discuss major research trends in 2024.
|Webinar
Emerging Science

Biomarkers: The key to earlier cancer detection and patient outcomes

CAS and Excelra delved into data surrounding biomarkers and their relationship to cancer to identify key targets for future study.
|Insights Report
Biotechnology

How biomarkers unlock faster cancer detection, improving outcomes

As cancer is projected to increase, finding stronger therapeutics is more urgent. Biomarkers offer a potential solution for better diagnosis and treatment.
|Article
Drug Discovery

Unveiling the potential of the antibody drug conjugate

Since 2018, research interest in antibody-drug conjugates has increased exponentially, due to their potential in the fight against cancer.
|Article
Emerging Science

Webinar on gut microbiome-brain alliance: The connection to health and disorders

CAS, Bayer, and Caltech explore how the gut-brain axis influences health from IBS to autism.
|Webinar
Emerging Science

Aging reimagined: Exploring the potential of anti-aging treatment strategies

Discover the latest in anti-aging treatment strategies to promote health and longevity, including stem cell therapies, hyaluronic acid, senolytics, gene therapy, and more.
|Article
Biotechnology

Webinar on nature’s lipid nanoparticles: Exosomes

Exosomes have enormous potential in drug delivery, diagnostics, and more. Mayo Clinic, Direct Biologics, and Aruna Bio discuss the full landscape.
|Webinar
Drug Discovery

Exosome research: from platelet dust to pioneering therapeutics

Landscape view of emerging contributors, companies, and researchers in the emerging field of exosome research. This article overviews key players in diagnostics and therapeutic fields of exosome research with a deeper look into the current clinical pipeline.
|Article
Drug Discovery

ACS webinar on molecular glues and targeted protein degradation

Expert panelists include Dr. Benjamin Ebert, the chair of Medical Oncology at the Dana-Farber Institute, Dr. Phil Chamberlain, the co-founder, President, and CEO of Neomorph, and Janet Sasso, an information scientist specializing in Life Sciences at CAS.
|Webinar
Digital R&D

The rise of AI drug development technology

Drug development is rapidly changing, which requires pharma companies to pivot. This is where AI drug development comes in, applying new technology to tackle an old problem.
|Article
Drug Discovery

Why the omicron BA.5 variant evades vaccines

As COVID-19 cases rise again worldwide, the Omicron subvariant BA.5 is currently the dominant strain. This blog explores some key mutations that increase transmission, evade protective antibodies, and increase the rate of (re)infection.
|Article
Biotechnology

Molecular glues and induced proximity: solving the undruggable

Molecular glues have been used to uncover new therapeutic agents. Because of their targeted protein degradation that holds them together, these glues have exciting potential in uncovering new drugs to fight cancer, immune diseases, and more.
|Article
Biotechnology

A therapeutic revolution: RNA in COVID-19 and beyond

We are in the midst of a therapeutic revolution, according to the authors of a recent review article in Frontiers in Bioengineering and Biotechnology.
|Article
Biotechnology

COVID-19 vaccine boosters: what does the research show?

With recent mRNA booster recommendations, many ask if they should get a COVID-19 booster and what the science shows? This blog explains the science of boosters, reviews current recommendations, and examines recent research.
|Article